Alterity Historical Balance Sheet

ATHE Stock

USD 1.06 0.01 0.95%

Trend analysis of Alterity Therapeutics balance sheet accounts such as Total Stockholder Equity of 19.2 M, Cash of 15.7 M or Cash And Short Term Investments of 15.7 M provides information on Alterity Therapeutics' total assets, liabilities, and equity, which is the actual value of Alterity Therapeutics to its prevalent stockholders. By breaking down trends over time using Alterity Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Alterity Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Alterity Therapeutics is a good buy for the upcoming year.

Alterity Therapeutics Inventory

(21,269.55)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.

About Alterity Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Alterity Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Alterity Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Alterity Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Alterity currently owns. An asset can also be divided into two categories, current and non-current.

Alterity Therapeutics Balance Sheet Chart

At present, Alterity Therapeutics' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Cash is expected to grow to about 15.7 M, whereas Total Current Assets are forecasted to decline to about 18.7 M.

Total Assets Cash And Short Term Investments Common Stock Shares Outstanding Total Current Assets Retained Earnings

Add Fundamental

Total Assets

Total assets refers to the total amount of Alterity Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Alterity Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Alterity Therapeutics balance sheet. This account contains Alterity Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Alterity Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Most accounts from Alterity Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Alterity Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.At present, Alterity Therapeutics' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Cash is expected to grow to about 15.7 M, whereas Total Current Assets are forecasted to decline to about 18.7 M.

	2021	2022	2023	2024 (projected)
Common Stock	213.8M	214.0M	223.2M	114.0M
Total Current Assets	41.1M	27.0M	19.0M	18.7M

Common Stock Total Current Assets

Alterity Therapeutics balance sheet Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Current Assets	Common Stock	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Inventory	Other Current Assets	Total Liab	Intangible Assets	Common Stock Total Equity	Non Current Liabilities Total	Property Plant And Equipment Gross	Short Long Term Debt Total	Current Deferred Revenue
Total Assets		0.99	-0.98	0.98	0.98	0.16	-0.73	1.0	0.61	0.27	0.51	0.04	-0.41	0.47	-0.52	-0.23	0.75	0.22	0.18	0.51	-0.31	0.57	0.16	0.14	-0.42	-0.45
Total Stockholder Equity	0.99		-0.99	0.99	0.99	0.1	-0.76	0.99	0.54	0.21	0.42	-0.03	-0.34	0.43	-0.49	-0.15	0.72	0.17	0.12	0.42	-0.33	0.5	0.09	0.07	-0.44	-0.39
Net Debt	-0.98	-0.99		-1.0	-1.0	-0.02	0.83	-0.98	-0.52	-0.15	-0.41	0.08	0.27	-0.43	0.47	0.07	-0.64	-0.11	-0.02	-0.4	0.34	-0.48	0.01	0.0	0.44	0.33
Cash	0.98	0.99	-1.0		1.0	0.06	-0.81	0.98	0.51	0.18	0.41	-0.08	-0.29	0.42	-0.48	-0.09	0.63	0.1	0.05	0.41	-0.34	0.48	0.01	0.03	-0.43	-0.35
Cash And Short Term Investments	0.98	0.99	-1.0	1.0		0.06	-0.81	0.98	0.51	0.18	0.41	-0.08	-0.29	0.42	-0.48	-0.09	0.63	0.1	0.05	0.41	-0.34	0.48	0.01	0.02	-0.43	-0.35
Common Stock Shares Outstanding	0.16	0.1	-0.02	0.06	0.06		0.4	0.13	0.55	0.89	0.63	0.66	-0.85	0.09	-0.25	-0.91	0.18	0.28	0.95	0.64	0.36	0.59	0.77	0.88	-0.06	-0.75
Other Stockholder Equity	-0.73	-0.76	0.83	-0.81	-0.81	0.4		-0.75	-0.25	0.33	-0.1	0.32	-0.12	-0.46	0.22	-0.35	-0.34	0.06	0.42	-0.09	0.31	-0.21	0.33	0.4	0.49	-0.09
Total Current Assets	1.0	0.99	-0.98	0.98	0.98	0.13	-0.75		0.61	0.23	0.51	0.03	-0.38	0.47	-0.52	-0.2	0.75	0.23	0.15	0.51	-0.31	0.57	0.14	0.11	-0.42	-0.43
Common Stock	0.61	0.54	-0.52	0.51	0.51	0.55	-0.25	0.61		0.52	0.79	0.42	-0.86	0.34	-0.69	-0.61	0.66	0.5	0.53	0.79	-0.05	0.99	0.6	0.46	-0.36	-0.73
Other Current Liab	0.27	0.21	-0.15	0.18	0.18	0.89	0.33	0.23	0.52		0.58	0.44	-0.8	-0.13	-0.37	-0.8	0.22	0.14	0.79	0.59	0.07	0.55	0.56	0.75	-0.01	-0.74
Total Current Liabilities	0.51	0.42	-0.41	0.41	0.41	0.63	-0.1	0.51	0.79	0.58		0.63	-0.72	0.57	-0.44	-0.76	0.59	0.5	0.63	1.0	0.11	0.77	0.62	0.68	-0.04	-0.74
Property Plant And Equipment Net	0.04	-0.03	0.08	-0.08	-0.08	0.66	0.32	0.03	0.42	0.44	0.63		-0.48	0.35	0.18	-0.82	0.26	0.72	0.8	0.64	0.69	0.4	0.83	0.88	0.1	-0.53
Retained Earnings	-0.41	-0.34	0.27	-0.29	-0.29	-0.85	-0.12	-0.38	-0.86	-0.8	-0.72	-0.48		-0.18	0.66	0.81	-0.46	-0.4	-0.78	-0.73	-0.03	-0.88	-0.76	-0.69	0.27	0.83
Accounts Payable	0.47	0.43	-0.43	0.42	0.42	0.09	-0.46	0.47	0.34	-0.13	0.57	0.35	-0.18		-0.07	-0.27	0.5	0.41	0.15	0.57	0.14	0.29	0.32	0.24	-0.29	-0.2
Non Current Assets Total	-0.52	-0.49	0.47	-0.48	-0.48	-0.25	0.22	-0.52	-0.69	-0.37	-0.44	0.18	0.66	-0.07		0.22	-0.52	-0.14	-0.16	-0.44	0.66	-0.7	-0.2	-0.06	0.19	0.54
Non Currrent Assets Other	-0.23	-0.15	0.07	-0.09	-0.09	-0.91	-0.35	-0.2	-0.61	-0.8	-0.76	-0.82	0.81	-0.27	0.22		-0.36	-0.55	-0.94	-0.77	-0.39	-0.6	-0.86	-0.93	-0.09	0.85
Net Receivables	0.75	0.72	-0.64	0.63	0.63	0.18	-0.34	0.75	0.66	0.22	0.59	0.26	-0.46	0.5	-0.52	-0.36		0.54	0.29	0.59	-0.24	0.61	0.42	0.24	-0.27	-0.47
Inventory	0.22	0.17	-0.11	0.1	0.1	0.28	0.06	0.23	0.5	0.14	0.5	0.72	-0.4	0.41	-0.14	-0.55	0.54		0.46	0.51	0.27	0.42	0.76	0.59	-0.05	-0.42
Other Current Assets	0.18	0.12	-0.02	0.05	0.05	0.95	0.42	0.15	0.53	0.79	0.63	0.8	-0.78	0.15	-0.16	-0.94	0.29	0.46		0.64	0.43	0.55	0.86	0.93	0.04	-0.77
Total Liab	0.51	0.42	-0.4	0.41	0.41	0.64	-0.09	0.51	0.79	0.59	1.0	0.64	-0.73	0.57	-0.44	-0.77	0.59	0.51	0.64		0.12	0.77	0.64	0.7	-0.04	-0.75
Intangible Assets	-0.31	-0.33	0.34	-0.34	-0.34	0.36	0.31	-0.31	-0.05	0.07	0.11	0.69	-0.03	0.14	0.66	-0.39	-0.24	0.27	0.43	0.12		-0.06	0.47	0.47	0.09	-0.09
Common Stock Total Equity	0.57	0.5	-0.48	0.48	0.48	0.59	-0.21	0.57	0.99	0.55	0.77	0.4	-0.88	0.29	-0.7	-0.6	0.61	0.42	0.55	0.77	-0.06		0.59	0.46	-0.38	-0.72
Non Current Liabilities Total	0.16	0.09	0.01	0.01	0.01	0.77	0.33	0.14	0.6	0.56	0.62	0.83	-0.76	0.32	-0.2	-0.86	0.42	0.76	0.86	0.64	0.47	0.59		0.85	-0.05	-0.7
Property Plant And Equipment Gross	0.14	0.07	0.0	0.03	0.02	0.88	0.4	0.11	0.46	0.75	0.68	0.88	-0.69	0.24	-0.06	-0.93	0.24	0.59	0.93	0.7	0.47	0.46	0.85		0.06	-0.67
Short Long Term Debt Total	-0.42	-0.44	0.44	-0.43	-0.43	-0.06	0.49	-0.42	-0.36	-0.01	-0.04	0.1	0.27	-0.29	0.19	-0.09	-0.27	-0.05	0.04	-0.04	0.09	-0.38	-0.05	0.06		-0.17
Current Deferred Revenue	-0.45	-0.39	0.33	-0.35	-0.35	-0.75	-0.09	-0.43	-0.73	-0.74	-0.74	-0.53	0.83	-0.2	0.54	0.85	-0.47	-0.42	-0.77	-0.75	-0.09	-0.72	-0.7	-0.67	-0.17

Click cells to compare fundamentals

Alterity Therapeutics Account Relationship Matchups

Alterity Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	13.3M	33.6M	41.4M	27.3M	19.2M	21.8M
Total Stockholder Equity	10.5M	30.5M	35.5M	22.8M	13.8M	19.2M
Net Debt	(9.2M)	(28.0M)	(34.7M)	(15.6M)	(12.5M)	(13.1M)
Cash	9.2M	28.1M	34.8M	15.8M	12.6M	15.7M
Cash And Short Term Investments	9.2M	28.1M	34.8M	15.8M	12.6M	15.7M
Common Stock Shares Outstanding	1.5M	2.8M	4.0M	4.0M	6.1M	6.4M
Liabilities And Stockholders Equity	13.3M	33.6M	41.4M	27.3M	19.2M	21.8M
Other Stockholder Equity	(4.3M)	(20.8M)	(22.0M)	4.0M	4.8M	8.7M
Total Current Assets	13.2M	33.5M	41.1M	27.0M	19.0M	18.7M
Common Stock	160.7M	197.4M	213.8M	214.0M	223.2M	114.0M
Other Current Liab	1.2M	1.6M	3.1M	2.5M	4.7M	4.9M
Total Current Liabilities	2.7M	3.1M	5.8M	4.4M	5.4M	2.8M
Property Plant And Equipment Net	71.4K	96.8K	218.5K	268.9K	186.9K	105.7K
Retained Earnings	(151.0M)	(169.7M)	(181.9M)	(195.1M)	(214.2M)	(203.5M)
Accounts Payable	954.0K	1.4M	2.6M	1.7M	581.1K	552.1K
Non Current Assets Total	71.4K	96.8K	218.5K	268.9K	186.9K	177.5K
Non Currrent Assets Other	(49.3K)	(96.8K)	(218.5K)	(268.9K)	(242.0K)	(229.9K)
Net Receivables	3.5M	4.1M	4.7M	8.6M	4.0M	2.9M
Inventory	567.9K	2.0	1.6M	2.6M	(22.4K)	(21.3K)
Other Current Assets	10.3K	1.2M	1.7M	2.6M	2.4M	2.5M
Total Liab	2.8M	3.1M	5.9M	4.5M	5.4M	2.9M
Common Stock Total Equity	143.9M	156.6M	160.7M	197.4M	227.1M	128.1M
Non Current Liabilities Total	42.4K	47.7K	73.6K	122.7K	51.9K	68.3K
Property Plant And Equipment Gross	71.4K	96.8K	733.1K	728.8K	619.1K	650.0K
Accumulated Other Comprehensive Income	866.1K	2.8M	3.6M	4.0M	4.8M	5.0M
Short Long Term Debt Total	33.7K	65.6K	117.5K	210.4K	159.0K	131.6K
Short Term Debt	32.9K	27.7K	57.6K	107.2K	107.1K	105.8K
Other Assets	(0.53)	0.03	(0.48)	1.0	0.9	0.86
Other Liab	41.5K	9.8K	13.8K	19.5K	22.4K	15.0K
Net Tangible Assets	7.2M	30.5M	35.5M	22.8M	26.2M	24.6M
Capital Lease Obligations	33.7K	65.6K	117.5K	210.4K	159.0K	167.0K
Property Plant Equipment	71.4K	96.8K	218.5K	268.9K	309.2K	324.7K
Net Invested Capital	7.2M	30.5M	35.5M	22.8M	13.8M	22.8M
Net Working Capital	7.1M	30.4M	35.3M	22.7M	13.7M	22.7M
Capital Stock	160.7M	197.4M	213.8M	214.0M	223.2M	213.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports:

How To Invest In Alterity

Details

Is Alterity Stock a good investment?

Details

What is Alterity Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.86)

Revenue Per Share

0.6

Quarterly Revenue Growth

0.384

Return On Assets

(0.53)

Return On Equity

(1.04)

The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alterity Historical Balance Sheet

Alterity Therapeutics Inventory

(21,269.55)

About Alterity Balance Sheet Analysis

Alterity Therapeutics Balance Sheet Chart

Total Assets

Cash And Short Term Investments

Common Stock Shares Outstanding

Total Current Assets

Retained Earnings

Alterity Therapeutics balance sheet Correlations

Alterity Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alterity Therapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 1.0	Total Current Liabilities
Total Stockholder Equity	+ 0.99	Total Assets
Cash	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Total Current Assets	- 0.98	Net Debt
Net Debt	- 0.98	Total Assets
Other Current Assets	- 0.94	Non Currrent Assets Other